Welcome to our dedicated page for Sight Sciences news (Ticker: $SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sight Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sight Sciences's position in the market.
Sight Sciences, Inc. (Nasdaq: SGHT) will present at the Bank of America Healthcare Conference, showcasing innovative eyecare technologies. The presentation will take place on May 14, 2024, accessible via live webcast.
Sight Sciences reported first quarter 2024 financial results, generating $19.3 million in total revenue, an increase of 2% compared to the prior year. The company achieved an 86% total gross margin and reduced cash used to $10.8 million. Additionally, a positive jury trial verdict was received in a patent infringement case, awarding $5.5 million in lost profits and $28.5 million in royalty damages. Clinical highlights included successful results from MIGS studies and the TearCare System trials. Despite a 32% decrease in Dry Eye revenue, the company remains optimistic about growth opportunities in the Surgical Glaucoma and Dry Eye segments for 2024.
Sight Sciences, Inc. (Nasdaq: SGHT) won a $34 million patent infringement case against Alcon for their Hydrus Microstent in a positive jury trial verdict. The damages include $5.5 million in lost profits and $28.5 million in royalty damages. The verdict is subject to appeal.